Do-Hyun Nam mainly focuses on Cancer research, Stem cell, Glioma, Cancer and Cancer cell. In the subject of general Cancer research, his work in Temozolomide is often linked to Somatic hypermutation, thereby combining diverse domains of study. His study in Stem cell is interdisciplinary in nature, drawing from both Wnt signaling pathway, Signal transduction, Transplantation and Pathology.
Do-Hyun Nam combines subjects such as Radioresistance, Isocitrate dehydrogenase and Kinase with his study of Glioma. His Cancer research is multidisciplinary, relying on both Radiosurgery, Glioblastoma, Confidence interval and Gene expression profiling. His research integrates issues of Cell and In vivo in his study of Cancer cell.
The scientist’s investigation covers issues in Cancer research, Surgery, Internal medicine, Cancer and Pathology. His work carried out in the field of Cancer research brings together such families of science as Cancer cell, Metastasis and Stem cell. As a part of the same scientific family, Do-Hyun Nam mostly works in the field of Internal medicine, focusing on Oncology and, on occasion, Glioblastoma.
His Cancer study incorporates themes from Brain tumor and Bioinformatics. Do-Hyun Nam regularly ties together related areas like Brain metastasis in his Pathology studies. His research investigates the link between Angiogenesis and topics such as In vivo that cross with problems in Pharmacology.
Do-Hyun Nam mainly investigates Cancer research, Glioblastoma, Glioma, Internal medicine and Cancer. His biological study spans a wide range of topics, including Cancer cell, Phenotype, Metastasis and Stem cell. Do-Hyun Nam interconnects T lymphocyte, CD8, Magnetic resonance imaging, Epitope and Immunotherapy in the investigation of issues within Glioblastoma.
His work on Temozolomide as part of general Glioma research is frequently linked to Somatic hypermutation, thereby connecting diverse disciplines of science. In his study, Survival rate and Transcriptome is strongly linked to Oncology, which falls under the umbrella field of Internal medicine. His Cancer research is multidisciplinary, incorporating perspectives in Viability assay and Drug.
His primary areas of study are Cancer research, Glioma, Glioblastoma, Cancer cell and Tumor microenvironment. His Cancer research study combines topics from a wide range of disciplines, such as Carcinogenesis, Cancer, Transcriptome, Stem cell and ATRX. His research in Glioma intersects with topics in Brain tumor, Germline mutation and Secondary Glioblastoma, IDH1.
His work deals with themes such as Glycocalyx, Glycoprotein, Integrin, Magnetic resonance imaging and Extracellular matrix, which intersect with Glioblastoma. His Cancer cell research is multidisciplinary, incorporating elements of Cell, Gene expression, Transactivation and Signal transduction, Cell biology. As a part of the same scientific study, he usually deals with the Temozolomide, concentrating on Regulation of gene expression and frequently concerns with Oncology and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma
Myung Jin Son;Kevin D Woolard;Do Hyun Nam;Jeongwu Lee.
Cell Stem Cell (2009)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.
Hyon Bin Na;Jung Hee Lee;Kwangjin An;Yong Il Park.
Angewandte Chemie (2007)
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells
Eunhee Kim;Misuk Kim;Dong Hun Woo;Yongjae Shin.
Cancer Cell (2013)
Clonal evolution of glioblastoma under therapy.
Jiguang Wang;Emanuela Cazzato;Erik Ladewig;Veronique Frattini.
Nature Genetics (2016)
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Kyeung Min Joo;Shi Yean Kim;Xun Jin;Sang Yong Song.
Laboratory Investigation (2008)
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang;Do-Hyun Nam;Zvi Ram;Wai-Sang Poon.
Cancer Letters (2016)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors;Karen L. Fink;Tom Mikkelsen;Danica Grujicic.
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Jinkuk Kim;Jinkuk Kim;In Hee Lee;Hee Jin Cho;Hee Jin Cho;Chul Kee Park.
Cancer Cell (2015)
WNT signaling in glioblastoma and therapeutic opportunities.
Yeri Lee;Jin Ku Lee;Sun Hee Ahn;Jeongwu Lee.
Laboratory Investigation (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: